IgE Receptor: Key To Immune System and Cancer (G932)

Target Name: MS4A3

NCBI ID: G932

IgE Receptor: Key To Immune System and Cancer

Mucous membranes play a crucial role in maintaining the body's barrier function, and their integrity is closely associated with various inflammatory and autoimmune disorders. Mucous membranes are composed of two main types of cells: epithelial and connective tissue cells. Among the epithelial cells, there is a subgroup of specialized cells called Mucous Epithelial Cells (MECs), which are responsible for maintaining the tight barrier between the epithelial tissue and the underlying connective tissue. This barrier function is dynamically regulated, and dysregulation of its integrity can lead to various inflammatory and autoimmune diseases, including atopic dermatitis, asthma, and inflammatory bowel disease.

One of the key components of the barrier function is the immunoglobulin E (IgE) receptor, also known as the Fc portion of the IgE molecule. IgE is a type of immunoglobulin that is primarily expressed in MECs, and it plays a crucial role in regulating the rapid and immediate allergic responses to allergens. IgE receptor is involved in the regulation of allergic reactions, as well as in the regulation of inflammation and inflammation-related tissue damage.

The IgE receptor is a transmembrane protein that consists of two subunits: the alpha subunit and the beta subunit. The alpha subunit is the extracellular portion of the receptor, while the beta subunit is the intracellular portion. The beta subunit is the target of many drugs that are used to treat allergies and asthma.

Drugs that target the IgE receptor have been shown to be effective in treating various inflammatory and autoimmune disorders. One of the most effective of these drugs is called terlipressin (TLX), which is a type of oral corticosteroid that is used to treat asthma and other allergies. TLX works by targeting the beta subunit of the IgE receptor and preventing its interaction with histamine. This results in the suppression of allergic symptoms and improved lung function.

Other drugs that target the IgE receptor include feosaglattein (FSA), which is a peptide-conjugated monoclonal antibody that is used to treat food allergies, and stromal cell-derived factor (SCDF), which is a cytokine that is used to treat skin conditions.

In addition to its use in treating allergies and asthma, the IgE receptor is also being targeted as a potential biomarker for certain types of cancer. The recognition of allergens by the IgE receptor is a well-established hallmark of cancer, and the use of drugs that target the receptor has been shown to be effective in inhibiting the growth of cancer cells.

Conclusion

The IgE receptor is a key component of the immune system that plays a crucial role in maintaining the barrier function and regulating allergic responses. Its dysfunction has been implicated in the development of various inflammatory and autoimmune disorders. The use of drugs that target the IgE receptor, such as terlipressin and feosaglattein, has been shown to be effective in treating asthma and other allergies. Additionally, the IgE receptor is also being targeted as a potential biomarker for certain types of cancer. Further research is needed to fully understand the role of the IgE receptor in the immune system and its potential as a drug target.

Protein Name: Membrane Spanning 4-domains A3

Functions: Hematopoietic modulator for the G1-S cell cycle transition. Modulates the level of phosphorylation of cyclin-dependent kinase 2 (CDK2) through its direct binding to cyclin-dependent kinase inhibitor 3 (CDKN3/KAP)

More Common Targets